AGMB Earnings Date: Nov 14, 2026 (Estimated) — AgomAb Therapeutics N.V. American Depositary Shares

NASDAQ · Healthcare · Biotechnology

Updated Oct 26, 2026

Price $7.30

Market Cap $445.7M

P/E -10.2

52W Range $6.61 – $17.82

Next Earnings Nov 14, 2026 · Before open (est.)

When is AGMB's next earnings date?

AgomAb Therapeutics N.V. American Depositary Shares (AGMB) is expected to report Q3 2026 earnings on Saturday, November 14, 2026 at 7:10 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.42.

How did AGMB do in its last earnings report?

In its most recent report on Aug 6, 2026 (H1 2026), AgomAb Therapeutics N.V. American Depositary Shares posted EPS of -$0.93 versus the $1.18 estimate, a miss of 178.8%. Revenue was $0. The stock's 1-day post-earnings move was +7.4%.

How much does AGMB stock move after earnings?

AGMB beat EPS estimates in 0 of its last 2 reported quarters. Over the last 2 reports the stock moved an average of 5.3% (up or down) in the day after earnings.

About AgomAb Therapeutics N.V. American Depositary Shares

AgomAb Therapeutics N.V. is a clinical-stage biopharmaceutical company dedicated to developing novel, disease-modifying therapies. Its primary focus lies in immunology and inflammatory ailments, particularly chronic fibrotic conditions where significant unmet medical needs persist. Its innovative pipeline features several promising candidates, including Ontunisertib (AGMB-129), an orally administered, gastrointestinal-restricted small molecule inhibitor targeting ALK5 or TGFßR1, designed to treat Fibrostenosing Crohn's disease and presently undergoing Phase 2a clinical trials. Also in development is AGMB-447, an inhaled small molecule that similarly inhibits ALK5 or TGFßR1, intended for idiopathic pulmonary fibrosis and currently in Phase 1 clinical studies. Furthermore, the company is advancing AGMB-101, a monoclonal antibody designed to mimic HGF. This agent exerts its effects through the agonism or stimulation of the MET receptor, having demonstrated both antifibrotic and regenerative capabilities in preclinical models. Established in 2017, AgomAb Therapeutics maintains its headquarters in Antwerp, Belgium.